Due to the fast growing field of molecular cardiology, mechanisms responsible for collateral artery growth (arteriogenesis) are widely unravelled. After coronary artery occlusion, flow shear stress induces endothelial cell expression and release of adhesion molecules and chemokines. Monocytes are attracted and transmigrate into the vessel wall to release pro-arteriogenic molecules. The process of collateral vessel growth is severely impaired in patients with different risk factors for atherosclerosis, as diabetes or hyperlipedemia. This can be attributed to the impaired migration capacity of monocytes towards pro-arteriogenic stimuli, like MCP-1 and VEGF-A. In these patients “at risk”, blood derived monocytes offer a possibility to predict the individual ability to form functional collaterals by an in vitro performed migration assay. Furthermore, growth factor therapy can be used to enhance and restore collateral growth in patients with impaired arteriogenesis. Here, the migration assay could perfectly be used to for individual adjustment of therapeutical interventions.
Table of Contents
1 Introduction
2 General Concepts of Arteriogenesis
3 Those Who Play the Game
3.1 The Endothelium
3.2 Arteriogenic Stimuli
3.2.1 MCP-1
3.2.1 VEGF
3.2.3 PlGF
3.2.4 FGF
4 How can it go wrong? Impairment of Arteriogenesis
5 To the Clinic: Prognosis and Future Therapy
5.1 Concrete Role of Monocytes
5.2 The Way to Predict Collateral Growth
5.3 Future Therapy
6 Discussion and Conclusion
Objectives and Research Focus
The primary objective of this work is to elucidate the mechanisms of arteriogenesis and its role in rescuing cardiac tissue from ischemia. The paper investigates how underlying pathologies in patients with risk factors impair these mechanisms and explores the potential for predicting individual collateral growth capacities through monocyte function assays, as well as the prospects for future pro-arteriogenic therapies.
- The physiological mechanisms of collateral artery growth (arteriogenesis).
- The impact of cardiovascular risk factors on collateral formation.
- Methods to evaluate individual arteriogenic potential using monocyte migration assays.
- Current challenges and future directions in growth factor-based therapeutic interventions.
Excerpt from the Publication
2 General Concepts of Arteriogenesis
Physiological blood vessels growth does not happen in an adult organism, with the exception of the female reproductive system. However, under pathophysiological circumstances, like tissue repair, the de novo growth and sprouting of new capillaries (angiogenesis) and the growth and remodelling of pre-existing collateral anastomoses (arteriogenesis), can be observed. [7,8,9] The main stimulus for angiogenesis is ischemia, with an up regulation of hypoxic factors like hypoxia-inducible factor (HIF) 1-alpha and vascular endothelial growth factor (VEGF), [5,7,10] whereas biomechanical forces, mainly fluid shear stress (FSS), induce the process of arteriogenesis. [7,11] A third form of vessel growth is vasculogenesis. In this process of de novo development of blood vessels, restricted to the embryonic phase, mesodermal cells give rise to angioblasts. [5,9] It is expected that pre existing interconnection that can grow out to functioning collaterals are already created from the vascular plexus by vasculogenesis during the embryological phase. [3] Angiogenesis alone cannot sufficiently restore adequate tissue perfusion after the event of cardiac arterial occlusion. In fact, large diameter vessels are needed instead of small capillaries because only muscular arteries can assure the transport of blood over longer distances. The process of arteriogenesis takes place by mitosis of endothelial cells (ECs) and smooth muscle cells (SMCs) of pre-existing anastomoses under the influence of several growth signals. [12] Following maturation, collaterals only differ minor in histological aspects from other arteries, with a muscular wall and more collagen. From more importance is their difference in anatomical appearance. They are more tortuous and re-entry in the distal part of the occluded artery with a non-physiological angle (figure 2).
Summary of Chapters
1 Introduction: Provides an overview of cardiovascular disease and introduces arteriogenesis as a natural compensatory mechanism for tissue perfusion.
2 General Concepts of Arteriogenesis: Defines arteriogenesis in contrast to angiogenesis and vasculogenesis, highlighting mechanical forces as the primary driver.
3 Those Who Play the Game: Details the cellular participants and specific molecular stimuli, such as MCP-1, VEGF, PlGF, and FGF, in the collateral growth process.
4 How can it go wrong? Impairment of Arteriogenesis: Examines how risk factors like diabetes and hyperlipidemia negatively impact the collateralization process.
5 To the Clinic: Prognosis and Future Therapy: Discusses the role of monocytes as functional parameters for prognosis and evaluates current and emerging therapeutic strategies.
6 Discussion and Conclusion: Summarizes the potential for individual risk assessment using monocyte function tests and addresses the controversies surrounding current therapeutic approaches.
Keywords
Arteriogenesis, Collateral Growth, Ischemia, Monocytes, Angiogenesis, Growth Factors, VEGF, MCP-1, Cardiovascular Disease, Endothelial Cells, Prognosis, Therapeutic Intervention, Cell Signaling, Atherosclerosis, Fluid Shear Stress.
Frequently Asked Questions
What is the primary focus of this work?
This paper focuses on the biological process of arteriogenesis—the growth of collateral arteries—and how this mechanism can be utilized or enhanced to improve blood flow in patients with severe coronary artery disease.
What are the central thematic areas?
The work covers molecular signaling pathways in collateral growth, the cellular role of monocytes, the negative influence of metabolic risk factors, and the evaluation of potential pro-arteriogenic therapies.
What is the main goal or research question?
The primary goal is to determine how we can move from theoretical understanding to clinical application, specifically by using monocyte migration as a functional diagnostic tool and developing effective growth factor-based therapies.
Which scientific methods are primarily discussed?
The publication reviews various animal models, in vitro chemotaxis assays (Boyden chambers), and clinical observations to evaluate the efficacy of different therapeutic agents and cellular functions.
What is treated in the main body?
The main body systematically covers the biological mechanisms of arteriogenesis, the specific roles of endothelial cells and growth factors, the factors that impair this process, and clinical strategies to restore or enhance collateral growth.
Which keywords characterize this paper?
The paper is characterized by terms such as arteriogenesis, collateral growth, vascular remodeling, monocyte function, and therapeutic angiogenesis.
How do risk factors like diabetes specifically hinder arteriogenesis?
According to the text, these risk factors impair the migration capacity of monocytes towards pro-arteriogenic stimuli like MCP-1 and VEGF, thereby preventing the necessary recruitment of cells to the site of injury.
Why are monocytes referred to as "living biosensors"?
Monocytes are described this way because they circulate through the body and reflect the metabolic condition of the patient in real-time; testing their function can reveal systemic dysfunctions that affect the patient's individual ability to form collaterals.
Is combination therapy more effective than single-agent therapy?
The study indicates that combination therapies (e.g., using multiple angiogenic and arteriogenic factors) often yield superior results in increasing collateral network density and blood flow compared to single-agent interventions.
- Quote paper
- Darius Henatsch (Author), 2008, Arteriogenesis - Prognosis and Therapeutical Potential , Munich, GRIN Verlag, https://www.grin.com/document/134742
